SciClone Pharmaceuticals, Valuation

SciClone Pharmaceuticals, seems to be undervalued based on Macroaxis valuation methodology. This module measures value of SciClone Pharmaceuticals, from inspecting the company fundamentals such as Operating Margin of 25.82%, Return On Equity of 19.56% and Shares Outstanding of 52.19M as well as reviewing its technical indicators and Probability Of Bankruptcy. In general, we recommend to buy undervalued stocks and to dispose of overvalued stocks since at some point securities prices and their ongoing real values will draw towards each other.
Investments

Valuation Drivers Correlation

Click cells to compare fundamentals   View All Correlations
SciClone Pharmaceuticals, In Valuation Data Drivers
Net Income Per Employee    Enterprise Value    Market Capitalization    
Horizon     30 Days    Login   to change
SciClone Pharmaceuticals, In is currently regarded as top stock in price to earning category among related companies. It is rated below average in price to book category among related companies fabricating about  0.17  of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for SciClone Pharmaceuticals, In is roughly  5.90 

Valuation Indicators

SciClone Pharmaceuticals, Valuation Fundamental Ratios

Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also World Market Map. Please also try Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Search macroaxis.com